Then, later in life and if IGF-1R inhibitors are truly specific for senescent cells, the physician may subscribe such inhibitors for prevention of senescence-induced microenvironmental changes that might promote tumor survival and progression. This evidence concerns the gene IGF1R and neoplasm.